Press Releases

Drew Holzapfel Joins the Global CEO Initiative on Alzheimer’s Disease as Executive Director

April 1, 2013

CONTACT:
Kyle Moler

New Report Confirms Alzheimer’s as Global Killer on the Scale of Cancer and Heart Disease

March 19, 2013

Report finds that 1 in 3 Seniors die with Alzheimer’s disease

New Industry Initiative Calls for Global Action Plan to Stop Alzheimer’s

March 5, 2013

The Global CEO Initiative on Alzheimer’s Disease (CEOi) Meets with European Parliament and Irish Council Presidency to Help Drive Collaboration, Innovation, and Business Leadership in the Fight Against Alzheimer’s Disease and Dementia

Brussels – Today, March 5, during a joint conference of the Irish Council Presidency and the European Parliament, leading global corporations urged the development of a Global Alzheimer’s Action Plan to diagnose, prevent and treat Alzheimer's disease by 2025.

Sequester Threatens Critical Blow to Alzheimer’s Research

March 4, 2013

National Institutes of Health takes 7.6 percent budget cut, jeopardizing Alzheimer’s research funding

WASHINGTON, D.C. – Washington’s failure to reach a deficit reduction deal before the March 1 sequester deadline has triggered once unthinkable budget cuts that will take the National Institutes of Health (NIH) to the chopping block, and jeopardize life-saving medical research funding for costly and deadly diseases like Alzheimer’s.

USAgainstAlzheimer’s Applauds “Brain Mapping Project” to Unlock Answers to Alzheimer’s

February 20, 2013

George Vradenburg, Chairman of USAgainstAlzheimer’s, issued the following statement in response to the news that the Obama Administration is planning to launch a public-private effort to map the human brain.

Why 2020?

USAgainstAlzheimer’s has retained its goal of stopping Alzheimer’s by 2020 rather than endorsing the goal of the National Plan to Address Alzheimer’s Disease that calls for preventing and effectively treating the disease by 2025. While we support the national plan and its goals, we believe, as most every family touched by Alzheimer’s disease believes, that preventing and effectively treating Alzheimer's by 2025 is simply too long a wait for concrete progress. There are promising avenues of drug discovery and development that will, if successful, deliver a means of slowing or deferring Alzheimer's symptoms by 2020. By voicing the urgency felt by so many families, we will pressure researchers and industry to do all in their power to make that happen.